Product Description
INB400 is a preclinical product candidate expanding the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or "off-the-shelf" DeltEx DRI therapy. We aim to take the clinical results from the ongoing INB-200 and INB-100 clinical trials to provide the safety data to support an IND submission for INB-400. The INB-400 product candidate will be a genetically modified DeltEx allogeneic candidate with an initial indication in newly diagnosed GBM. (Sourced from: https://in8bio.com/pipeline/)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: Orphan Drug - Glioblastoma *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IN8bio
Company Location: Eastern America
Company CEO: William Ho
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - IN8bio presented P2 Oncology results on 2024-05-29 for INB-400
- Clinical Outcomes Reported - IN8bio presented P1 Glioblastoma results on 2023-11-17 for INB-400
Highest Development Phases
Phase 0: Glioblastoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/12/2026 |
News Article |
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma |
|
12/19/2025 |
News Article |
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager |
|
02/26/2025 |
News Article |
IN8bio to Present at the TD Cowen 45th Annual Health Care Conference |
|
02/24/2025 |
News Article |
IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference |